Global Nanomedicines

Nanomedicines Comprehensive Study by Application (Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Immunology, Infectious Diseases), Type (Therapeutics (Biologics and Small Molecules), Diagnostics (IVD, Imaging, and Others), Medical Devices (Regenerative Medicine, and Implants)), End User (Hospitals and Clinics,, Diagnostics Laboratories, Research and Academic Institutes), Molecule Type (Nanoparticles (Lipid Based, Polymers & Polymer Drug Conjugates, Inorganic Nanoparticles), Nanoshells, Nanotubes, Nanodevices) Players and Region - Global Market Outlook to 2032

Nanomedicines Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled

Report Objectives / Segmentation Covered

By Application
  • Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Immunology
  • Infectious Diseases
By Type
  • Therapeutics [Biologics and Small Molecules]
  • Diagnostics [IVD, Imaging, and Others]
  • Medical Devices [Regenerative Medicine, and Implants]

By End User
  • Hospitals and Clinics,
  • Diagnostics Laboratories
  • Research and Academic Institutes

By Molecule Type
  • Nanoparticles [Lipid Based, Polymers & Polymer Drug Conjugates, Inorganic Nanoparticles]
  • Nanoshells
  • Nanotubes
  • Nanodevices

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Factor Analysis
    • 3.1. Porters Five Forces
    • 3.2. Supply/Value Chain
    • 3.3. PESTEL analysis
    • 3.4. Market Entropy
    • 3.5. Patent/Trademark Analysis
  • 4. Global Nanomedicines, by Application, Type, End User, Molecule Type and Region (value) (2019-2024)
    • 4.1. Introduction
    • 4.2. Global Nanomedicines (Value)
      • 4.2.1. Global Nanomedicines by: Type (Value)
        • 4.2.1.1. Therapeutics [Biologics and Small Molecules]
        • 4.2.1.2. Diagnostics [IVD, Imaging, and Others]
        • 4.2.1.3. Medical Devices [Regenerative Medicine, and Implants]
      • 4.2.2. Global Nanomedicines by: Application (Value)
        • 4.2.2.1. Oncology
        • 4.2.2.2. Neurodegenerative Diseases
        • 4.2.2.3. Cardiovascular Diseases
        • 4.2.2.4. Immunology
        • 4.2.2.5. Infectious Diseases
      • 4.2.3. Global Nanomedicines by: Type (Value)
        • 4.2.3.1. Therapeutics [Biologics and Small Molecules]
        • 4.2.3.2. Diagnostics [IVD, Imaging, and Others]
        • 4.2.3.3. Medical Devices [Regenerative Medicine, and Implants]
      • 4.2.4. Global Nanomedicines by: End User (Value)
        • 4.2.4.1. Hospitals and Clinics,
        • 4.2.4.2. Diagnostics Laboratories
        • 4.2.4.3. Research and Academic Institutes
      • 4.2.5. Global Nanomedicines by: Molecule Type (Value)
        • 4.2.5.1. Nanoparticles [Lipid Based, Polymers & Polymer Drug Conjugates, Inorganic Nanoparticles]
        • 4.2.5.2. Nanoshells
        • 4.2.5.3. Nanotubes
        • 4.2.5.4. Nanodevices
      • 4.2.6. Global Nanomedicines Region
        • 4.2.6.1. South America
          • 4.2.6.1.1. Brazil
          • 4.2.6.1.2. Argentina
          • 4.2.6.1.3. Rest of South America
        • 4.2.6.2. Asia Pacific
          • 4.2.6.2.1. China
          • 4.2.6.2.2. Japan
          • 4.2.6.2.3. India
          • 4.2.6.2.4. South Korea
          • 4.2.6.2.5. Taiwan
          • 4.2.6.2.6. Australia
          • 4.2.6.2.7. Rest of Asia-Pacific
        • 4.2.6.3. Europe
          • 4.2.6.3.1. Germany
          • 4.2.6.3.2. France
          • 4.2.6.3.3. Italy
          • 4.2.6.3.4. United Kingdom
          • 4.2.6.3.5. Netherlands
          • 4.2.6.3.6. Rest of Europe
        • 4.2.6.4. MEA
          • 4.2.6.4.1. Middle East
          • 4.2.6.4.2. Africa
        • 4.2.6.5. North America
          • 4.2.6.5.1. United States
          • 4.2.6.5.2. Canada
          • 4.2.6.5.3. Mexico
  • 5. Nanomedicines: Manufacturers/Players Analysis
    • 5.1. Competitive Landscape
      • 5.1.1. Market Share Analysis
        • 5.1.1.1. Top 3
        • 5.1.1.2. Top 5
    • 5.2. Peer Group Analysis (2024)
    • 5.3. BCG Matrix
    • 5.4. Company Profile
      • 5.4.1. Abbott
        • 5.4.1.1. Business Overview
        • 5.4.1.2. Products/Services Offerings
        • 5.4.1.3. Financial Analysis
        • 5.4.1.4. SWOT Analysis
      • 5.4.2. GE Healthcare
        • 5.4.2.1. Business Overview
        • 5.4.2.2. Products/Services Offerings
        • 5.4.2.3. Financial Analysis
        • 5.4.2.4. SWOT Analysis
      • 5.4.3. Johnson & Johnson
        • 5.4.3.1. Business Overview
        • 5.4.3.2. Products/Services Offerings
        • 5.4.3.3. Financial Analysis
        • 5.4.3.4. SWOT Analysis
      • 5.4.4. Merck
        • 5.4.4.1. Business Overview
        • 5.4.4.2. Products/Services Offerings
        • 5.4.4.3. Financial Analysis
        • 5.4.4.4. SWOT Analysis
      • 5.4.5. Pfizer
        • 5.4.5.1. Business Overview
        • 5.4.5.2. Products/Services Offerings
        • 5.4.5.3. Financial Analysis
        • 5.4.5.4. SWOT Analysis
      • 5.4.6. CombiMatrix
        • 5.4.6.1. Business Overview
        • 5.4.6.2. Products/Services Offerings
        • 5.4.6.3. Financial Analysis
        • 5.4.6.4. SWOT Analysis
      • 5.4.7. Celgene
        • 5.4.7.1. Business Overview
        • 5.4.7.2. Products/Services Offerings
        • 5.4.7.3. Financial Analysis
        • 5.4.7.4. SWOT Analysis
      • 5.4.8. Mallinckrodt
        • 5.4.8.1. Business Overview
        • 5.4.8.2. Products/Services Offerings
        • 5.4.8.3. Financial Analysis
        • 5.4.8.4. SWOT Analysis
      • 5.4.9. Sigma-Tau Pharmaceuticals
        • 5.4.9.1. Business Overview
        • 5.4.9.2. Products/Services Offerings
        • 5.4.9.3. Financial Analysis
        • 5.4.9.4. SWOT Analysis
      • 5.4.10. Teva Pharmaceutical
        • 5.4.10.1. Business Overview
        • 5.4.10.2. Products/Services Offerings
        • 5.4.10.3. Financial Analysis
        • 5.4.10.4. SWOT Analysis
      • 5.4.11. Nanosphere
        • 5.4.11.1. Business Overview
        • 5.4.11.2. Products/Services Offerings
        • 5.4.11.3. Financial Analysis
        • 5.4.11.4. SWOT Analysis
      • 5.4.12. UCB SA
        • 5.4.12.1. Business Overview
        • 5.4.12.2. Products/Services Offerings
        • 5.4.12.3. Financial Analysis
        • 5.4.12.4. SWOT Analysis
  • 6. Global Nanomedicines Sale, by Application, Type, End User, Molecule Type and Region (value) (2027-2032)
    • 6.1. Introduction
    • 6.2. Global Nanomedicines (Value)
      • 6.2.1. Global Nanomedicines by: Type (Value)
        • 6.2.1.1. Therapeutics [Biologics and Small Molecules]
        • 6.2.1.2. Diagnostics [IVD, Imaging, and Others]
        • 6.2.1.3. Medical Devices [Regenerative Medicine, and Implants]
      • 6.2.2. Global Nanomedicines by: Application (Value)
        • 6.2.2.1. Oncology
        • 6.2.2.2. Neurodegenerative Diseases
        • 6.2.2.3. Cardiovascular Diseases
        • 6.2.2.4. Immunology
        • 6.2.2.5. Infectious Diseases
      • 6.2.3. Global Nanomedicines by: Type (Value)
        • 6.2.3.1. Therapeutics [Biologics and Small Molecules]
        • 6.2.3.2. Diagnostics [IVD, Imaging, and Others]
        • 6.2.3.3. Medical Devices [Regenerative Medicine, and Implants]
      • 6.2.4. Global Nanomedicines by: End User (Value)
        • 6.2.4.1. Hospitals and Clinics,
        • 6.2.4.2. Diagnostics Laboratories
        • 6.2.4.3. Research and Academic Institutes
      • 6.2.5. Global Nanomedicines by: Molecule Type (Value)
        • 6.2.5.1. Nanoparticles [Lipid Based, Polymers & Polymer Drug Conjugates, Inorganic Nanoparticles]
        • 6.2.5.2. Nanoshells
        • 6.2.5.3. Nanotubes
        • 6.2.5.4. Nanodevices
      • 6.2.6. Global Nanomedicines Region
        • 6.2.6.1. South America
          • 6.2.6.1.1. Brazil
          • 6.2.6.1.2. Argentina
          • 6.2.6.1.3. Rest of South America
        • 6.2.6.2. Asia Pacific
          • 6.2.6.2.1. China
          • 6.2.6.2.2. Japan
          • 6.2.6.2.3. India
          • 6.2.6.2.4. South Korea
          • 6.2.6.2.5. Taiwan
          • 6.2.6.2.6. Australia
          • 6.2.6.2.7. Rest of Asia-Pacific
        • 6.2.6.3. Europe
          • 6.2.6.3.1. Germany
          • 6.2.6.3.2. France
          • 6.2.6.3.3. Italy
          • 6.2.6.3.4. United Kingdom
          • 6.2.6.3.5. Netherlands
          • 6.2.6.3.6. Rest of Europe
        • 6.2.6.4. MEA
          • 6.2.6.4.1. Middle East
          • 6.2.6.4.2. Africa
        • 6.2.6.5. North America
          • 6.2.6.5.1. United States
          • 6.2.6.5.2. Canada
          • 6.2.6.5.3. Mexico
  • 7. Appendix
    • 7.1. Acronyms
  • 8. Methodology and Data Source
    • 8.1. Methodology/Research Approach
      • 8.1.1. Research Programs/Design
      • 8.1.2. Market Size Estimation
      • 8.1.3. Market Breakdown and Data Triangulation
    • 8.2. Data Source
      • 8.2.1. Secondary Sources
      • 8.2.2. Primary Sources
    • 8.3. Disclaimer
List of Tables
  • Table 1. Nanomedicines: by Type(USD Million)
  • Table 2. Nanomedicines Therapeutics [Biologics and Small Molecules] , by Region USD Million (2019-2024)
  • Table 3. Nanomedicines Diagnostics [IVD, Imaging, and Others] , by Region USD Million (2019-2024)
  • Table 4. Nanomedicines Medical Devices [Regenerative Medicine, and Implants] , by Region USD Million (2019-2024)
  • Table 5. Nanomedicines: by Application(USD Million)
  • Table 6. Nanomedicines Oncology , by Region USD Million (2019-2024)
  • Table 7. Nanomedicines Neurodegenerative Diseases , by Region USD Million (2019-2024)
  • Table 8. Nanomedicines Cardiovascular Diseases , by Region USD Million (2019-2024)
  • Table 9. Nanomedicines Immunology , by Region USD Million (2019-2024)
  • Table 10. Nanomedicines Infectious Diseases , by Region USD Million (2019-2024)
  • Table 11. Nanomedicines: by Type(USD Million)
  • Table 12. Nanomedicines Therapeutics [Biologics and Small Molecules] , by Region USD Million (2019-2024)
  • Table 13. Nanomedicines Diagnostics [IVD, Imaging, and Others] , by Region USD Million (2019-2024)
  • Table 14. Nanomedicines Medical Devices [Regenerative Medicine, and Implants] , by Region USD Million (2019-2024)
  • Table 15. Nanomedicines: by End User(USD Million)
  • Table 16. Nanomedicines Hospitals and Clinics, , by Region USD Million (2019-2024)
  • Table 17. Nanomedicines Diagnostics Laboratories , by Region USD Million (2019-2024)
  • Table 18. Nanomedicines Research and Academic Institutes , by Region USD Million (2019-2024)
  • Table 19. Nanomedicines: by Molecule Type(USD Million)
  • Table 20. Nanomedicines Nanoparticles [Lipid Based, Polymers & Polymer Drug Conjugates, Inorganic Nanoparticles] , by Region USD Million (2019-2024)
  • Table 21. Nanomedicines Nanoshells , by Region USD Million (2019-2024)
  • Table 22. Nanomedicines Nanotubes , by Region USD Million (2019-2024)
  • Table 23. Nanomedicines Nanodevices , by Region USD Million (2019-2024)
  • Table 24. South America Nanomedicines, by Country USD Million (2019-2024)
  • Table 25. South America Nanomedicines, by Application USD Million (2019-2024)
  • Table 26. South America Nanomedicines, by Type USD Million (2019-2024)
  • Table 27. South America Nanomedicines, by End User USD Million (2019-2024)
  • Table 28. South America Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 29. Brazil Nanomedicines, by Application USD Million (2019-2024)
  • Table 30. Brazil Nanomedicines, by Type USD Million (2019-2024)
  • Table 31. Brazil Nanomedicines, by End User USD Million (2019-2024)
  • Table 32. Brazil Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 33. Argentina Nanomedicines, by Application USD Million (2019-2024)
  • Table 34. Argentina Nanomedicines, by Type USD Million (2019-2024)
  • Table 35. Argentina Nanomedicines, by End User USD Million (2019-2024)
  • Table 36. Argentina Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 37. Rest of South America Nanomedicines, by Application USD Million (2019-2024)
  • Table 38. Rest of South America Nanomedicines, by Type USD Million (2019-2024)
  • Table 39. Rest of South America Nanomedicines, by End User USD Million (2019-2024)
  • Table 40. Rest of South America Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 41. Asia Pacific Nanomedicines, by Country USD Million (2019-2024)
  • Table 42. Asia Pacific Nanomedicines, by Application USD Million (2019-2024)
  • Table 43. Asia Pacific Nanomedicines, by Type USD Million (2019-2024)
  • Table 44. Asia Pacific Nanomedicines, by End User USD Million (2019-2024)
  • Table 45. Asia Pacific Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 46. China Nanomedicines, by Application USD Million (2019-2024)
  • Table 47. China Nanomedicines, by Type USD Million (2019-2024)
  • Table 48. China Nanomedicines, by End User USD Million (2019-2024)
  • Table 49. China Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 50. Japan Nanomedicines, by Application USD Million (2019-2024)
  • Table 51. Japan Nanomedicines, by Type USD Million (2019-2024)
  • Table 52. Japan Nanomedicines, by End User USD Million (2019-2024)
  • Table 53. Japan Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 54. India Nanomedicines, by Application USD Million (2019-2024)
  • Table 55. India Nanomedicines, by Type USD Million (2019-2024)
  • Table 56. India Nanomedicines, by End User USD Million (2019-2024)
  • Table 57. India Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 58. South Korea Nanomedicines, by Application USD Million (2019-2024)
  • Table 59. South Korea Nanomedicines, by Type USD Million (2019-2024)
  • Table 60. South Korea Nanomedicines, by End User USD Million (2019-2024)
  • Table 61. South Korea Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 62. Taiwan Nanomedicines, by Application USD Million (2019-2024)
  • Table 63. Taiwan Nanomedicines, by Type USD Million (2019-2024)
  • Table 64. Taiwan Nanomedicines, by End User USD Million (2019-2024)
  • Table 65. Taiwan Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 66. Australia Nanomedicines, by Application USD Million (2019-2024)
  • Table 67. Australia Nanomedicines, by Type USD Million (2019-2024)
  • Table 68. Australia Nanomedicines, by End User USD Million (2019-2024)
  • Table 69. Australia Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 70. Rest of Asia-Pacific Nanomedicines, by Application USD Million (2019-2024)
  • Table 71. Rest of Asia-Pacific Nanomedicines, by Type USD Million (2019-2024)
  • Table 72. Rest of Asia-Pacific Nanomedicines, by End User USD Million (2019-2024)
  • Table 73. Rest of Asia-Pacific Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 74. Europe Nanomedicines, by Country USD Million (2019-2024)
  • Table 75. Europe Nanomedicines, by Application USD Million (2019-2024)
  • Table 76. Europe Nanomedicines, by Type USD Million (2019-2024)
  • Table 77. Europe Nanomedicines, by End User USD Million (2019-2024)
  • Table 78. Europe Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 79. Germany Nanomedicines, by Application USD Million (2019-2024)
  • Table 80. Germany Nanomedicines, by Type USD Million (2019-2024)
  • Table 81. Germany Nanomedicines, by End User USD Million (2019-2024)
  • Table 82. Germany Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 83. France Nanomedicines, by Application USD Million (2019-2024)
  • Table 84. France Nanomedicines, by Type USD Million (2019-2024)
  • Table 85. France Nanomedicines, by End User USD Million (2019-2024)
  • Table 86. France Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 87. Italy Nanomedicines, by Application USD Million (2019-2024)
  • Table 88. Italy Nanomedicines, by Type USD Million (2019-2024)
  • Table 89. Italy Nanomedicines, by End User USD Million (2019-2024)
  • Table 90. Italy Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 91. United Kingdom Nanomedicines, by Application USD Million (2019-2024)
  • Table 92. United Kingdom Nanomedicines, by Type USD Million (2019-2024)
  • Table 93. United Kingdom Nanomedicines, by End User USD Million (2019-2024)
  • Table 94. United Kingdom Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 95. Netherlands Nanomedicines, by Application USD Million (2019-2024)
  • Table 96. Netherlands Nanomedicines, by Type USD Million (2019-2024)
  • Table 97. Netherlands Nanomedicines, by End User USD Million (2019-2024)
  • Table 98. Netherlands Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 99. Rest of Europe Nanomedicines, by Application USD Million (2019-2024)
  • Table 100. Rest of Europe Nanomedicines, by Type USD Million (2019-2024)
  • Table 101. Rest of Europe Nanomedicines, by End User USD Million (2019-2024)
  • Table 102. Rest of Europe Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 103. MEA Nanomedicines, by Country USD Million (2019-2024)
  • Table 104. MEA Nanomedicines, by Application USD Million (2019-2024)
  • Table 105. MEA Nanomedicines, by Type USD Million (2019-2024)
  • Table 106. MEA Nanomedicines, by End User USD Million (2019-2024)
  • Table 107. MEA Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 108. Middle East Nanomedicines, by Application USD Million (2019-2024)
  • Table 109. Middle East Nanomedicines, by Type USD Million (2019-2024)
  • Table 110. Middle East Nanomedicines, by End User USD Million (2019-2024)
  • Table 111. Middle East Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 112. Africa Nanomedicines, by Application USD Million (2019-2024)
  • Table 113. Africa Nanomedicines, by Type USD Million (2019-2024)
  • Table 114. Africa Nanomedicines, by End User USD Million (2019-2024)
  • Table 115. Africa Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 116. North America Nanomedicines, by Country USD Million (2019-2024)
  • Table 117. North America Nanomedicines, by Application USD Million (2019-2024)
  • Table 118. North America Nanomedicines, by Type USD Million (2019-2024)
  • Table 119. North America Nanomedicines, by End User USD Million (2019-2024)
  • Table 120. North America Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 121. United States Nanomedicines, by Application USD Million (2019-2024)
  • Table 122. United States Nanomedicines, by Type USD Million (2019-2024)
  • Table 123. United States Nanomedicines, by End User USD Million (2019-2024)
  • Table 124. United States Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 125. Canada Nanomedicines, by Application USD Million (2019-2024)
  • Table 126. Canada Nanomedicines, by Type USD Million (2019-2024)
  • Table 127. Canada Nanomedicines, by End User USD Million (2019-2024)
  • Table 128. Canada Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 129. Mexico Nanomedicines, by Application USD Million (2019-2024)
  • Table 130. Mexico Nanomedicines, by Type USD Million (2019-2024)
  • Table 131. Mexico Nanomedicines, by End User USD Million (2019-2024)
  • Table 132. Mexico Nanomedicines, by Molecule Type USD Million (2019-2024)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Nanomedicines: by Type(USD Million)
  • Table 146. Nanomedicines Therapeutics [Biologics and Small Molecules] , by Region USD Million (2027-2032)
  • Table 147. Nanomedicines Diagnostics [IVD, Imaging, and Others] , by Region USD Million (2027-2032)
  • Table 148. Nanomedicines Medical Devices [Regenerative Medicine, and Implants] , by Region USD Million (2027-2032)
  • Table 149. Nanomedicines: by Application(USD Million)
  • Table 150. Nanomedicines Oncology , by Region USD Million (2027-2032)
  • Table 151. Nanomedicines Neurodegenerative Diseases , by Region USD Million (2027-2032)
  • Table 152. Nanomedicines Cardiovascular Diseases , by Region USD Million (2027-2032)
  • Table 153. Nanomedicines Immunology , by Region USD Million (2027-2032)
  • Table 154. Nanomedicines Infectious Diseases , by Region USD Million (2027-2032)
  • Table 155. Nanomedicines: by Type(USD Million)
  • Table 156. Nanomedicines Therapeutics [Biologics and Small Molecules] , by Region USD Million (2027-2032)
  • Table 157. Nanomedicines Diagnostics [IVD, Imaging, and Others] , by Region USD Million (2027-2032)
  • Table 158. Nanomedicines Medical Devices [Regenerative Medicine, and Implants] , by Region USD Million (2027-2032)
  • Table 159. Nanomedicines: by End User(USD Million)
  • Table 160. Nanomedicines Hospitals and Clinics, , by Region USD Million (2027-2032)
  • Table 161. Nanomedicines Diagnostics Laboratories , by Region USD Million (2027-2032)
  • Table 162. Nanomedicines Research and Academic Institutes , by Region USD Million (2027-2032)
  • Table 163. Nanomedicines: by Molecule Type(USD Million)
  • Table 164. Nanomedicines Nanoparticles [Lipid Based, Polymers & Polymer Drug Conjugates, Inorganic Nanoparticles] , by Region USD Million (2027-2032)
  • Table 165. Nanomedicines Nanoshells , by Region USD Million (2027-2032)
  • Table 166. Nanomedicines Nanotubes , by Region USD Million (2027-2032)
  • Table 167. Nanomedicines Nanodevices , by Region USD Million (2027-2032)
  • Table 168. South America Nanomedicines, by Country USD Million (2027-2032)
  • Table 169. South America Nanomedicines, by Application USD Million (2027-2032)
  • Table 170. South America Nanomedicines, by Type USD Million (2027-2032)
  • Table 171. South America Nanomedicines, by End User USD Million (2027-2032)
  • Table 172. South America Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 173. Brazil Nanomedicines, by Application USD Million (2027-2032)
  • Table 174. Brazil Nanomedicines, by Type USD Million (2027-2032)
  • Table 175. Brazil Nanomedicines, by End User USD Million (2027-2032)
  • Table 176. Brazil Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 177. Argentina Nanomedicines, by Application USD Million (2027-2032)
  • Table 178. Argentina Nanomedicines, by Type USD Million (2027-2032)
  • Table 179. Argentina Nanomedicines, by End User USD Million (2027-2032)
  • Table 180. Argentina Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 181. Rest of South America Nanomedicines, by Application USD Million (2027-2032)
  • Table 182. Rest of South America Nanomedicines, by Type USD Million (2027-2032)
  • Table 183. Rest of South America Nanomedicines, by End User USD Million (2027-2032)
  • Table 184. Rest of South America Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 185. Asia Pacific Nanomedicines, by Country USD Million (2027-2032)
  • Table 186. Asia Pacific Nanomedicines, by Application USD Million (2027-2032)
  • Table 187. Asia Pacific Nanomedicines, by Type USD Million (2027-2032)
  • Table 188. Asia Pacific Nanomedicines, by End User USD Million (2027-2032)
  • Table 189. Asia Pacific Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 190. China Nanomedicines, by Application USD Million (2027-2032)
  • Table 191. China Nanomedicines, by Type USD Million (2027-2032)
  • Table 192. China Nanomedicines, by End User USD Million (2027-2032)
  • Table 193. China Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 194. Japan Nanomedicines, by Application USD Million (2027-2032)
  • Table 195. Japan Nanomedicines, by Type USD Million (2027-2032)
  • Table 196. Japan Nanomedicines, by End User USD Million (2027-2032)
  • Table 197. Japan Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 198. India Nanomedicines, by Application USD Million (2027-2032)
  • Table 199. India Nanomedicines, by Type USD Million (2027-2032)
  • Table 200. India Nanomedicines, by End User USD Million (2027-2032)
  • Table 201. India Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 202. South Korea Nanomedicines, by Application USD Million (2027-2032)
  • Table 203. South Korea Nanomedicines, by Type USD Million (2027-2032)
  • Table 204. South Korea Nanomedicines, by End User USD Million (2027-2032)
  • Table 205. South Korea Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 206. Taiwan Nanomedicines, by Application USD Million (2027-2032)
  • Table 207. Taiwan Nanomedicines, by Type USD Million (2027-2032)
  • Table 208. Taiwan Nanomedicines, by End User USD Million (2027-2032)
  • Table 209. Taiwan Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 210. Australia Nanomedicines, by Application USD Million (2027-2032)
  • Table 211. Australia Nanomedicines, by Type USD Million (2027-2032)
  • Table 212. Australia Nanomedicines, by End User USD Million (2027-2032)
  • Table 213. Australia Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 214. Rest of Asia-Pacific Nanomedicines, by Application USD Million (2027-2032)
  • Table 215. Rest of Asia-Pacific Nanomedicines, by Type USD Million (2027-2032)
  • Table 216. Rest of Asia-Pacific Nanomedicines, by End User USD Million (2027-2032)
  • Table 217. Rest of Asia-Pacific Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 218. Europe Nanomedicines, by Country USD Million (2027-2032)
  • Table 219. Europe Nanomedicines, by Application USD Million (2027-2032)
  • Table 220. Europe Nanomedicines, by Type USD Million (2027-2032)
  • Table 221. Europe Nanomedicines, by End User USD Million (2027-2032)
  • Table 222. Europe Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 223. Germany Nanomedicines, by Application USD Million (2027-2032)
  • Table 224. Germany Nanomedicines, by Type USD Million (2027-2032)
  • Table 225. Germany Nanomedicines, by End User USD Million (2027-2032)
  • Table 226. Germany Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 227. France Nanomedicines, by Application USD Million (2027-2032)
  • Table 228. France Nanomedicines, by Type USD Million (2027-2032)
  • Table 229. France Nanomedicines, by End User USD Million (2027-2032)
  • Table 230. France Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 231. Italy Nanomedicines, by Application USD Million (2027-2032)
  • Table 232. Italy Nanomedicines, by Type USD Million (2027-2032)
  • Table 233. Italy Nanomedicines, by End User USD Million (2027-2032)
  • Table 234. Italy Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 235. United Kingdom Nanomedicines, by Application USD Million (2027-2032)
  • Table 236. United Kingdom Nanomedicines, by Type USD Million (2027-2032)
  • Table 237. United Kingdom Nanomedicines, by End User USD Million (2027-2032)
  • Table 238. United Kingdom Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 239. Netherlands Nanomedicines, by Application USD Million (2027-2032)
  • Table 240. Netherlands Nanomedicines, by Type USD Million (2027-2032)
  • Table 241. Netherlands Nanomedicines, by End User USD Million (2027-2032)
  • Table 242. Netherlands Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 243. Rest of Europe Nanomedicines, by Application USD Million (2027-2032)
  • Table 244. Rest of Europe Nanomedicines, by Type USD Million (2027-2032)
  • Table 245. Rest of Europe Nanomedicines, by End User USD Million (2027-2032)
  • Table 246. Rest of Europe Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 247. MEA Nanomedicines, by Country USD Million (2027-2032)
  • Table 248. MEA Nanomedicines, by Application USD Million (2027-2032)
  • Table 249. MEA Nanomedicines, by Type USD Million (2027-2032)
  • Table 250. MEA Nanomedicines, by End User USD Million (2027-2032)
  • Table 251. MEA Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 252. Middle East Nanomedicines, by Application USD Million (2027-2032)
  • Table 253. Middle East Nanomedicines, by Type USD Million (2027-2032)
  • Table 254. Middle East Nanomedicines, by End User USD Million (2027-2032)
  • Table 255. Middle East Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 256. Africa Nanomedicines, by Application USD Million (2027-2032)
  • Table 257. Africa Nanomedicines, by Type USD Million (2027-2032)
  • Table 258. Africa Nanomedicines, by End User USD Million (2027-2032)
  • Table 259. Africa Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 260. North America Nanomedicines, by Country USD Million (2027-2032)
  • Table 261. North America Nanomedicines, by Application USD Million (2027-2032)
  • Table 262. North America Nanomedicines, by Type USD Million (2027-2032)
  • Table 263. North America Nanomedicines, by End User USD Million (2027-2032)
  • Table 264. North America Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 265. United States Nanomedicines, by Application USD Million (2027-2032)
  • Table 266. United States Nanomedicines, by Type USD Million (2027-2032)
  • Table 267. United States Nanomedicines, by End User USD Million (2027-2032)
  • Table 268. United States Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 269. Canada Nanomedicines, by Application USD Million (2027-2032)
  • Table 270. Canada Nanomedicines, by Type USD Million (2027-2032)
  • Table 271. Canada Nanomedicines, by End User USD Million (2027-2032)
  • Table 272. Canada Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 273. Mexico Nanomedicines, by Application USD Million (2027-2032)
  • Table 274. Mexico Nanomedicines, by Type USD Million (2027-2032)
  • Table 275. Mexico Nanomedicines, by End User USD Million (2027-2032)
  • Table 276. Mexico Nanomedicines, by Molecule Type USD Million (2027-2032)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nanomedicines: by Type USD Million (2019-2024)
  • Figure 5. Global Nanomedicines: by Application USD Million (2019-2024)
  • Figure 6. Global Nanomedicines: by Type USD Million (2019-2024)
  • Figure 7. Global Nanomedicines: by End User USD Million (2019-2024)
  • Figure 8. Global Nanomedicines: by Molecule Type USD Million (2019-2024)
  • Figure 9. South America Nanomedicines Share (%), by Country
  • Figure 10. Asia Pacific Nanomedicines Share (%), by Country
  • Figure 11. Europe Nanomedicines Share (%), by Country
  • Figure 12. MEA Nanomedicines Share (%), by Country
  • Figure 13. North America Nanomedicines Share (%), by Country
  • Figure 14. Global Nanomedicines share by Players 2024 (%)
  • Figure 15. Global Nanomedicines share by Players (Top 3) 2024(%)
  • Figure 16. Global Nanomedicines share by Players (Top 5) 2024(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Revenue, Net Income and Gross profit
  • Figure 19. Abbott Revenue: by Geography 2024
  • Figure 20. GE Healthcare Revenue, Net Income and Gross profit
  • Figure 21. GE Healthcare Revenue: by Geography 2024
  • Figure 22. Johnson & Johnson Revenue, Net Income and Gross profit
  • Figure 23. Johnson & Johnson Revenue: by Geography 2024
  • Figure 24. Merck Revenue, Net Income and Gross profit
  • Figure 25. Merck Revenue: by Geography 2024
  • Figure 26. Pfizer Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Revenue: by Geography 2024
  • Figure 28. CombiMatrix Revenue, Net Income and Gross profit
  • Figure 29. CombiMatrix Revenue: by Geography 2024
  • Figure 30. Celgene Revenue, Net Income and Gross profit
  • Figure 31. Celgene Revenue: by Geography 2024
  • Figure 32. Mallinckrodt Revenue, Net Income and Gross profit
  • Figure 33. Mallinckrodt Revenue: by Geography 2024
  • Figure 34. Sigma-Tau Pharmaceuticals Revenue, Net Income and Gross profit
  • Figure 35. Sigma-Tau Pharmaceuticals Revenue: by Geography 2024
  • Figure 36. Teva Pharmaceutical Revenue, Net Income and Gross profit
  • Figure 37. Teva Pharmaceutical Revenue: by Geography 2024
  • Figure 38. Nanosphere Revenue, Net Income and Gross profit
  • Figure 39. Nanosphere Revenue: by Geography 2024
  • Figure 40. UCB SA Revenue, Net Income and Gross profit
  • Figure 41. UCB SA Revenue: by Geography 2024
  • Figure 42. Global Nanomedicines: by Type USD Million (2027-2032)
  • Figure 43. Global Nanomedicines: by Application USD Million (2027-2032)
  • Figure 44. Global Nanomedicines: by Type USD Million (2027-2032)
  • Figure 45. Global Nanomedicines: by End User USD Million (2027-2032)
  • Figure 46. Global Nanomedicines: by Molecule Type USD Million (2027-2032)
  • Figure 47. South America Nanomedicines Share (%), by Country
  • Figure 48. Asia Pacific Nanomedicines Share (%), by Country
  • Figure 49. Europe Nanomedicines Share (%), by Country
  • Figure 50. MEA Nanomedicines Share (%), by Country
  • Figure 51. North America Nanomedicines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott
  • GE Healthcare
  • Johnson & Johnson
  • Merck
  • Pfizer
  • CombiMatrix
  • Celgene
  • Mallinckrodt
  • Sigma-Tau Pharmaceuticals
  • Teva Pharmaceutical
  • Nanosphere
  • UCB SA
Select User Access Type

Key Highlights of Report


Feb 2025 225 Pages 58 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nanomedicines Quantitative research analysis
Global Nanomedicines Qualitative Industry Analysis
Global Nanomedicines Quantitative research analysis
Global Nanomedicines Qualitative Industry Analysis
Global Nanomedicines Quantitative research analysis
Global Nanomedicines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Nanomedicines Report?

Have a Query? Click Here

Other Related Reports

Body Contouring Comprehensive Study by Type (Non-Invasive (Laser-like Lipo, Infrared Light Lipo, Cryolipolysis, Laser Lipo and Radio frequency lipo), Invasive), Application (Hospitals, Medical Spas, ...
$ 3450
Hospital Asset Management Comprehensive Study by Type (Real-time Location Systems (RTLS), Radio-frequency Identification (RFID), Ultrasound, Infrared), Application (Hospital (Equipment, Patient Monit...
$ 3750
Procalcitonin Comprehensive Study by Type (Polyclonal Procalcitonin Antibody, Monoclonal Procalcitonin Antibody), Application (Diagnose Sepis, Diagnose Kidney Infections, Monitor the Effectivenees of...
$ 3450
Speech Therapy Services Comprehensive Study by Treatment (Articulation Therapy, Language Intervention Therapy, Oral Motor Therapy, VitalStim Therapy, LSVT (Lee Silverman Speech Therapy)), Indication ...
$ 3500
Radiation Dose Management Comprehensive Study by Type (Software, Services, Consulting Services, Others), Application (Hospitals and Clinics, Diagnostic Centers, Research Centers and Academic Medical ...
$ 3750
Ovulation Test Comprehensive Study by Type (Coloration Ovulation Test, Digital Ovulation Test), Application (Hospital Use, Home Use, Others) Players and Region - Global Market Outlook to 2032
$ 3500
Body Contouring Comprehensive Study by Type (Non-Invasive (Laser-like Lipo, Infrared Light Lipo, Cryolipolysis, Laser Lipo and Radio frequency lipo), Invasive), Application (Hospitals, Medical Spas, ...
$ 3450
Hospital Asset Management Comprehensive Study by Type (Real-time Location Systems (RTLS), Radio-frequency Identification (RFID), Ultrasound, Infrared), Application (Hospital (Equipment, Patient Monit...
$ 3750
Procalcitonin Comprehensive Study by Type (Polyclonal Procalcitonin Antibody, Monoclonal Procalcitonin Antibody), Application (Diagnose Sepis, Diagnose Kidney Infections, Monitor the Effectivenees of...
$ 3450
Speech Therapy Services Comprehensive Study by Treatment (Articulation Therapy, Language Intervention Therapy, Oral Motor Therapy, VitalStim Therapy, LSVT (Lee Silverman Speech Therapy)), Indication ...
$ 3500
Radiation Dose Management Comprehensive Study by Type (Software, Services, Consulting Services, Others), Application (Hospitals and Clinics, Diagnostic Centers, Research Centers and Academic Medical ...
$ 3750
Ovulation Test Comprehensive Study by Type (Coloration Ovulation Test, Digital Ovulation Test), Application (Hospital Use, Home Use, Others) Players and Region - Global Market Outlook to 2032
$ 3500
Body Contouring Comprehensive Study by Type (Non-Invasive (Laser-like Lipo, Infrared Light Lipo, Cryolipolysis, Laser Lipo and Radio frequency lipo), Invasive), Application (Hospitals, Medical Spas, ...
$ 3450
Hospital Asset Management Comprehensive Study by Type (Real-time Location Systems (RTLS), Radio-frequency Identification (RFID), Ultrasound, Infrared), Application (Hospital (Equipment, Patient Monit...
$ 3750
Procalcitonin Comprehensive Study by Type (Polyclonal Procalcitonin Antibody, Monoclonal Procalcitonin Antibody), Application (Diagnose Sepis, Diagnose Kidney Infections, Monitor the Effectivenees of...
$ 3450
Speech Therapy Services Comprehensive Study by Treatment (Articulation Therapy, Language Intervention Therapy, Oral Motor Therapy, VitalStim Therapy, LSVT (Lee Silverman Speech Therapy)), Indication ...
$ 3500